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Depression affects up to 30% of human immunodeficiency virus (HIV)-infected individuals. We estimated joint
effects of antiretroviral therapy (ART) initiation and depressive symptoms on time to death using a joint marginal
structural model and data from a cohort of HIV-infected women from the Women’s Interagency HIV Study (con-
ducted in the United States) from 1998–2011. Among 848 women contributing 6,721 years of follow-up, 194 parti-
cipants died during follow-up, resulting in a crude mortality rate of 2.9 per 100 women-years. Cumulative mortality
curves indicated greatest mortality for women who reported depressive symptoms and had not initiated ART. The
hazard ratio for depressive symptoms was 3.38 (95% confidence interval (CI): 2.15, 5.33) and for ART was 0.47
(95% CI: 0.31, 0.70). Using a reference category of women without depressive symptoms who had initiated ART,
the hazard ratio for women with depressive symptoms who had initiated ART was 3.60 (95% CI: 2.02, 6.43). For
women without depressive symptoms who had not started ART, the hazard ratio was 2.36 (95% CI: 1.16, 4.81).
Among women reporting depressive symptoms who had not started ART, the hazard ratio was 7.47 (95% CI:
3.91, 14.3). We found a protective effect of ART initiation on mortality, as well as a harmful effect of depressive
symptoms, in a cohort of HIV-infected women.
antiretroviral therapy; cohort studies; depression; HIV; marginal structural models; mortality; proportional hazards
models; women
Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; CES-D, Center for Epidemiologic
Studies Depression Scale; CI, confidence interval; HIV, human immunodeficiency virus; WIHS, Women’s Interagency HIV Study.
Depression is a chronic mental health condition that affects
up to 30% of human immunodeficiency virus (HIV)-infected
individuals (1–11). Major depressive disorder ordinarily is
diagnosed through a combination of diagnostic criteria and
clinical judgment (12, 13). Depression is rarely assessed in
clinical studies. Depressive symptoms, a critical component of
the diagnosis of depression, have been associated with higher
mortality in many (14–20) but not all (21) studies of HIV-
infected individuals. Lyketsos et al. (21) reported that depres-
sive symptoms were not associated with risk of acquired
immune deficiency syndrome (AIDS) or all-cause mortality
among HIV-infected adult men in the Multicenter AIDS
Cohort Study in the era before effective antiretroviral therapy
(ART). However, more recent studies in the combined ART
era noted strong effects of both ART and depressive symptoms
on virologic and clinical outcomes including mortality, often
in the context of investigations for racial disparities (14–16).
Two studies found that depressive symptoms were associated
with increased risk of mortality among HIV-infected adult
men in the Multicenter AIDS Cohort Study (16) and adult
women in theWomen’s Interagency HIV Study (WIHS) (15,
16). Murphy et al. (15) tested various domains of depressive
symptoms (somatic, positive, negative, and interpersonal)
and found each to be associated with AIDS mortality.
Depression and ARTmay interact with each other in influ-
encing all-cause mortality, and the presence or absence of
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such an interaction may be important in guiding optimal care
for individuals living with HIV (19, 22, 23). For example,
the effect of depression on mortality might be attenuated
among those who have initiated ART, especially in the mod-
ern treatment era with simpler and more robust regimens, as
patients achieve improved physical health potentially leading
to improved mental health (20, 24). If true, this might suggest
that mental health treatment may be less important for reducing
mortality in the current era of dramatically expanded ART
treatment. Alternatively, the effect of depression on mortality
may be comparable or even stronger among those initiating
ART because ART initiation introduces a new pathway—
ART adherence and care retention—through which depression
influences mortality. Results supporting this conclusion would
suggest that expanded depression treatment is equally impor-
tant to or even more important than efforts to reduce overall
mortality among HIV-infected adults.
In one important previous study, investigators examined
the potential for interaction between depressive symptoms
and adherence to ART and found no departures from multi-
plicative or additive effects (19). However, the investigators
did not control for time-varying confounding over follow-
up by variables such as CD4 cell count, and they examined
depressive symptoms for only 1 year after ART initiation.
We extend this work by focusing on a similar interaction but
in a longitudinal context with time-varying depressive symp-
toms over a longer follow-up period, with time-varying con-
founding controlled through the use of a marginal structural
model. Standard marginal structural model analyses have
previously indicated a survival benefit of ART (25); yet, to
our knowledge, no study has simultaneously examined the
joint effects of time-varying ART and depressive symptoms
on mortality. By joint effects, we mean the explicit estima-
tion of the effects of multiple exposures on a single outcome,
while adjusting for time-fixed and time-varying confounding
for both exposures (26, 27). We estimated the joint effects of
ART initiation and depressive symptoms on total mortality
using data from 848 HIV-infected adult women followed
from 1998 to 2011 in the WIHS.
METHODS
Study sample
A full description of the WIHS cohort is provided else-
where (28, 29). In brief, the WIHS is a prospective cohort
study with semiannual follow-up on key measures of HIV
disease history and progression, including self-reported med-
ication use, laboratory results, and self-reported behavioral
characteristics. Between 1994 and 2013, the WIHS enrolled
4,346 women from 10 sites across the United States; 3,232
(74%) were HIV-infected at enrollment. We used a new-user
cohort design (30), which limits the potential for bias due
to women surviving a previous period of ART therapy. To
examine a time period during which modern ART was the
predominant therapy, for this study we started follow-up at
WIHS visits beginning on April 1, 1998, and ended the study
period on December 31, 2011. A total of 583 women had no
visits during the study period, of whom 338 women had died
prior to April 1, 1998. We further excluded 1,761 prevalent
users of combination ART and 40 women who did not have
any information on CD4 cell count, HIV RNA viral load, or
Center for Epidemiologic Studies Depression Scale (CES-D)
score within 1 year of their first study visit after April 1, 1998.
Our analysis cohort included 848 HIV-infected women
who participated in the WIHS between April 1, 1998, and
December 31, 2011, and who had not initiated ART by April
1, 1998. All participants provided written informed consent,
and local institutional review boards reviewed all study
protocols.
Exposure assessment
The definition of ART was guided by the Department
of Health and Human Services/Kaiser Foundation Panel
guidelines (31). HIV-infected women in WIHS report use
of all antiretroviral drugs during the previous 6 months at
each study visit. We assumed that participants remain on
ART after initiation until they died, were lost to follow-
up, or were administratively censored, making our results
analogous to an intention-to-treat analysis in a randomized
controlled trial (32). We examined this assumption in a sensi-
tivity analysis where we allowed ART use to vary over time.
Given the interval design of our cohort, we set the first date of
ART as the midpoint between the first date reporting ART
and the last date not reporting ART. In the 8 cases where the
difference between these 2 dates was greater than 4 years, we
set the first date of ART as the first reported date of ART
minus 2 years.
Depressive symptoms were defined by scores from the
CES-D. The CES-D has been extensively validated and per-
forms well in comparison to longer clinical surveys of
depressive symptoms (33, 34). The CES-D score has a range
from 0–60, and a score of 16 or higher was classified as hav-
ing depressive symptoms; a score below 16 was classified
as not having depressive symptoms. WIHS participants re-
ported depressive symptoms at each semiannual visit. We al-
lowed depressive symptoms to vary over time. Furthermore,
some authors have noted the potential for overlap between
symptoms of somatic depression and HIV (15, 35). We inves-
tigated this with a sensitivity analysis in which we removed
the somatic items from the CES-D scale when determining
depressive symptoms.
Outcome ascertainment
Incident deaths were continuously ascertained through
medical record abstraction, health-care providers, personal
contacts, and contacts with local health departments. Addi-
tionally, for women lost to follow-up or known to have died,
National Death Index searches were performed on a yearly
basis through December 31, 2011. Administrative censoring
occurred at the last available National Death Index search
date.
Statistical analysis
Let = ( )⁎T T Cmin ,i i i , where Ti is the time, measured in
days, from study entry to death, andCi is the time to admin-
istrative censoring or loss to follow-up, for participant i.
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Women were considered lost to follow-up after 2 consecutive
missed visits, and they did not reenter the risk set if they came
back to the study at a later date. Let ( )X t and ( )D t be binary
indicators of ART initiation and depressive symptoms, respec-
tively, at day t . Let ( )Z tX be a vector denoting the levels of
confounders of X and T , while ( )V 0X is the vector subset of
( )Z tX corresponding to time-fixed confounders measured at
study entry. Define analogous vectors ( )Z tD , ( )Z tC , ( )V 0D ,
and ( )V 0C , which correspond to levels of time-varying and
time-fixed confounders of D and T and of C and T , respec-
tively. Overbars represent the history of a given random vari-
able from study entry, or ̅ ( ) = { ( ) ( ) … ( )}X t X X X t0 , 1 , , .
Then, let =̅ ( ) ̅ ( ) ̅ ̅T Tix t d t ix d, , represent the time to death for par-
ticipant i had she been assigned ART initiation history ̅ ( )x t
and depressive symptom history ̅ ( )d t during the study period,
rather than her observed histories ̅ ( )X t and ̅ ( )D t . Finally, let
= { }V V V V, ,X D C .
A marginal structural Cox proportional hazards model for
the joint effects of ̅ ( )x t and ̅ ( )d t on ̅ ̅Tix d, is λ ( ) =̅ ̅ tT x d,
λ ( ) (θ)t exp ,0 where θ = α ( )+ α ( ) + α ( ) ( )x t d t x t d t1 2 3 , λ ( )t0
is the baseline hazard function and λ ( )̅ ̅ tT x d, is the hazard func-
tion for ̅ ̅T x d, . We adjust for time-varying confounders using
inverse probability weights, which we describe below. The
parameter (α )exp 1 is the hazard ratio for the effect of ART
initiation on ̅ ̅T x d, with no depressive symptoms at time t ,
(α )exp 2 is the hazard ratio for the effect of depressive
symptoms at time t on ̅ ̅T x d, prior to ART initiation, and
(α )exp 3 is the ratio of hazard ratios for the joint effect of
ART initiation ̅ ( )x t and depressive symptoms ̅ ( )d t on ̅ ̅T x d, .
Let α = {α α α }, ,1 2 3 .
The joint marginal structural model above is fit in a two-
part process using inverse probability weights. Conditional
on the estimated weights, the weighted maximum partial
likelihood estimates for αˆ are obtained by maximizing
(α) = ∏ =
( ) (θ)
∑ ( ) ( ) (θ)
ˆ ( )
=
L i
n Y t
Y t W t
W t
1
exp
exp
i i
j
n
j i j i
i i
1
⎧⎨⎩
⎫⎬⎭ , where ( )Y ti is an
indicator that participant i is at risk at distinct ordered event time
t, the inverse probability weights ( ) = ( ) ( ) ( )W t W t W t W tX D C ,
and θ as defined above. Given necessary assumptions stated
below, αˆ are consistent asymptotically normal estimates of
the joint effects of ART initiation and depressive symptoms
on time to death accounting for time-varying confounding
as well as selection bias due to censoring informed by mea-
sured covariates. Therefore, αˆ3 can be used to assess the
presence of multiplicative interaction at time t . To assess
interaction on the additive scale, we calculated the relative
excess risk due to interaction.
The stabilized weights ( ) = ( ) ( ) ( )W t W t W t W tX D C can be
used to fit the joint marginal structural model above, and have
been previously described (36). The denominator for the ART
initiation weights ( )W tX are estimated from a pooled logistic
regression model { ( ) = } = {β ( ) + β′ ( )}X t x t Q tP expit j j0 1 ,
where = (·) { (·) + }expit exp exp 1 . β ( )tj0 are time-specific
intercepts, ( ) = { ̅ ( − ) ̅ ( − ) ̅ ( )}Q t X t D t Z t1 , 1 , , and β ( )tj1
is a vector of log hazard ratios for the effects of ( )Q t on ( )X t .
The numerator for the weights can be estimated from a pooled
logistic regression model with ( )V 0X replacing ̅ ( )Z t in ( )Q t .
A similar approach was taken to estimate the censoring
weights ( )W tC and depressive symptom weights ( )W tD .
The assumptions necessary for asymptotically consistent
estimation of α are treatment-variation irrelevance (essentially
consistency) (37), no interference (38), conditional exchange-
ability, positivity, and correct model specification (36, 39).
We included the following time-fixed covariates for the 3
weight equations: age at enrollment, white race, CD4 cell
count at enrollment, and HIV RNA viral load at enrollment.
Time-varying covariates included CD4 cell count, HIV
RNA viral load, and, for the model for time-varying depres-
sive symptoms only, depressive symptoms at the previous
visit. As a sensitivity analysis, we further included substance
abuse, defined as a time-varying covariate for the use of
either injected or noninjected drugs, in our weight equations.
Missing values for time-varying covariates were replaced by
values carried forward from the previous visit. Continuous
variables were modeled using restricted cubic splines, with 3
knots (at the 5th, 50th, and 95th percentiles). We explored
truncation at various percentiles and values of the weight dis-
tribution (36) as well as a marginal structural model without
a term for interaction between ART initiation and depressive
symptoms. In addition to the joint marginal structural Cox
proportional hazards model, we also fitted unadjusted Cox
proportional hazards models. All data analysis and model fit-
ting was performed using SAS, version 9.3 (SAS Institute,
Inc., Cary, North Carolina).
RESULTS
Table 1 presents characteristics at entry and over follow-up
for the 848 women, who contributed a total of 6,721 years of
follow-up; 66% were black, and 38% had less than 12 years
of education. At study entry, the median age was 39, and the
median CES-D score was 16. The median length of follow-
up was 9.3 years, and the maximum was 13.7 years. A total
of 189 women were lost to follow-up, and 397 women were
administratively censored at the last date at which National
Death Index searches were available. A total of 194 partici-
pants died during follow-up, resulting in a mortality rate of
2.9 per 100 women-years. Averaged over the 6,721 years of
follow-up, the median CES-D score was 12, and 60% of
women-years were after ART initiation. The joint exposure
status of the cohort over successive visits is shown in Figure 1.
The proportion of women who were experiencing no depres-
sive symptoms and had started ART increased over time
from 37% after approximately 5 years to 50% after approxi-
mately 10 years. The proportion of women who experienced
depressive symptoms and had initiated ART increased to
approximately 27% after approximately 5 years, but remained
relatively constant around 30% afterwards. The most preva-
lent regimens over follow-up were protease-inhibitor-based
regimens (43%) and nonnucleoside reverse transcriptase
inhibitor-based regimens (41%). We had complete data on
ART initiation, age, and race. Over the period of analysis,
77% of CES-D scores were available, and 91% of CD4 cell
count and HIV RNA viral load values were available.
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Table 1. Characteristics of the 848 Included HIV-Infected Women at Study Entry and During Follow-up, Women’s
Interagency HIV Study, United States, 1998–2011
Characteristic
At Entry (n = 848 Participants) During Follow-up (n = 6,721 Women-Years)a
Median (IQR) No. % Median (IQR) No. %
Age 39 (33–45) 43 (37–50)
ART use 4,028 60
CES-D scoreb 16 (7–27) 12 (4–24)
Mono- or dual-therapyc 263 31 939 14
CD4 cell count 440 (264–649) 444 (283–640)
Log10 HIV RNA 3.5 (2.7–4.3) 2.8 (2.3–4.0)
Race
White 162 19
Black 558 66
Other 128 15
Education, yearsd
<12 325 38
12 264 31
>12 257 30
Abbreviations: ART, antiretroviral therapy; CES-D, Center for Epidemiologic Studies Depression Scale; HIV,
human immunodeficiency virus; IQR, interquartile range.
a Median follow-up: 9.1 years; maximum follow-up: 13.7 years.
b Possible scores: 0–60.
c Mono- or dual-therapy is classified as any use of antiretroviral medications that does not qualify as ART (use of 3
or more antiretroviral drugs, including at least 1 of the following: a protease inhibitor, a nonnucleoside reverse tran-
scriptase inhibitor, one of the nucleoside reverse transcriptase inhibitors abacavir or tenofovir, an entry inhibitor, or
an integrase inhibitor).
d Two women were missing information on their educational history.
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Figure 1. Joint exposure status of antiretroviral therapy (ART) initiation and depressive symptoms in the Women’s Interagency HIV Study,
United States, 1998–2011. The proportion of women with depressive symptoms who had initiated ART is represented by the black shaded area,
women without depressive symptoms who had initiated ART by dark gray, women with depressive symptoms who had not initiated ART by light
gray, and women without depressive symptoms who had not initiated ART by white.
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We present 8-year cumulative mortality curves for ART
initiation, depressive symptoms, and the joint classification
of ART and depressive symptoms in Figure 2. These curves
are based upon the weighted marginal structural model re-
sults presented in Table 2. Cumulative mortality was higher
in participants who had depressive symptoms and had not
initiated ART (Figure 2). In the joint classification of ART
and depressive symptoms (Figure 3), participants who re-
ported depressive symptoms and had not initiated ART had
the highest cumulative mortality, while those women with-
out depressive symptoms who had initiated ART had the
lowest cumulative mortality over 8 years. We also present
unadjusted cumulative mortality curves (Web Figure 1, avail-
able at http://aje.oxfordjournals.org/); in the unadjusted results,
cumulative mortality was higher in both groups with depres-
sive symptoms.
Table 2 presents the crude and weighted incidence rates
and hazard ratios. The overall marginal effect of ART initia-
tion on mortality was 0.47 (95% confidence interval (CI):
0.31, 0.70), and the marginal effect of depressive symptoms
on mortality was 3.38 (95% CI: 2.15, 5.33). Setting women
who did not report depressive symptoms and had initiated
ART as a reference category, we found a strong harmful effect
of other combinations of these 2 exposures on mortality.
Women who reported depressive symptoms and had initi-
ated ART had a hazard ratio of 3.60 (95% CI: 2.02, 6.43).
The hazard ratio for women without depressive symptoms
who had not initiated ART was 2.36 (95% CI: 1.16, 4.81),
which was subject to substantial time-varying confounding.
For those women with depressive symptoms who had not ini-
tiated ART, the hazard ratio was 7.47 (95% CI: 3.91, 14.3).
The Wald test P value for the term for interaction between
ART initiation and depressive symptoms in the joint marginal
structural weighted model was 0.78, indicating no strong evi-
dence for departure from multiplicative effects. We also found
no significant deviation from additivity, with a relative excess
risk of interaction of −1.06 (95% CI: −2.90, 0.78).
In our sensitivity analysis allowing ART use to vary over
time, results were similar to those of our primary analysis,
with some attenuation towards the null value. The hazard
ratio for women with depressive symptoms who had initi-
ated ART was 2.34 (95% CI: 1.08, 5.08). For women with-
out depressive symptoms who had not initiated ART, the
hazard ratio was 1.64 (95% CI: 0.67, 4.01). For women with
depressive symptoms who had not initiated ART, the hazard
ratio was 4.27 (95% CI: 1.88, 9.70). Finally, when removing
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Figure 2. Effects of antiretroviral therapy (ART) initiation and depressive symptoms on cumulative mortality in the Women’s Interagency HIV
Study, United States, 1998–2011. Women who had not initiated ART are represented by the solid line and women who had initiated ART by the
dashed line (A). Women experiencing depressive symptoms are represented by the solid line and women not experiencing depressive symptoms
by the dashed line (B). Weighted models adjusted for age at enrollment, race, CD4 cell count, log10 HIV RNA, baseline CD4 cell count, and base-
line log10 HIV RNA. Weights for depressive symptoms also adjusted for depressive symptoms at the previous visit.
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somatic items from the calculation of the CES-D score, the
results were further attenuated. Women with depressive
symptoms who had not initiated ART had a hazard ratio of
3.32 (95% CI: 1.53, 7.20).
DISCUSSION
Using a joint marginal structural model, we found a strong
protective effect of ART initiation, and a strong harmful effect
of depressive symptoms on all-cause mortality in a cohort of
HIV-infected women. In a joint model, mortality among
women who either reported depressive symptoms or had not
initiated ART was greatly increased compared with women
who did not report depressive symptoms and had initiated
ART. Strikingly, the harmful effect on mortality of depressive
symptoms alone (hazard ratio = 3.60) was greater in magni-
tude than the effect on mortality of failing to initiate ART
alone (hazard ratio = 2.36). The effect of the combined expo-
sures was particularly strong in the scenario of no ART initia-
tion with depressive symptoms: Although the product term
was not statistically significant, the hazard of death for these
women was over 7 times that of women without depressive
symptoms who had initiated ART. Notably, our findings ech-
oed previous research in a British Columbia cohort, where
the hazard ratio for the effect of depressive symptoms among
patients with lower adherence to ARTwas 5.90 (19).
These findings tend to support the importance of effective
treatment of depression among women with HIV infection.
Conversely—and as expected—among patients with or with-
out depressive symptoms, ART initiation and adherence is
clearly critical. Notably, we did not find evidence of inter-
action between these 2 common exposures on either the
multiplicative or additive scale, in accordance with previ-
ous work (19). By assessing these very common exposures
jointly, we provide evidence that they do not combine
beyond what would be expected in a multiplicative or addi-
tive fashion.
Prior research has shown a strong protective effect of ART
initiation on mortality; our mortality hazard ratio of 0.47 (95%
CI: 0.31, 0.70) was similar to results from the Multicenter
AIDS Cohort Study/WIHS (25), and the HIV-CAUSAL
Table 2. Unadjusted and Weighted Joint Effects of ART Initiation and Depressive Symptoms on All-Cause
Mortality in the Women’s Interagency HIV Study, United States, 1998–2011
Model and ART/Depressive Symptom Status Deaths Women-Years IRa HR 95% CI P for Interactionb
Unadjusted
ART, no depressive symptoms 36 2,341 1.54 1 0.80
ART, depressive symptoms 86 1,686 5.10 3.35 2.26, 4.96
No ART, no depressive symptoms 19 1,506 1.26 0.88 0.50, 1.54
No ART, depressive symptoms 53 1,187 4.46 3.20 2.06, 4.97
Weightedc
ART, no depressive symptoms 34 2,548 1.35 1 0.78
ART, depressive symptoms 86 1,968 4.39 3.60 2.02, 6.43
No ART, no depressive symptoms 33 1,356 2.46 2.36 1.16, 4.81
No ART, depressive symptoms 86 1,136 7.55 7.47 3.91, 14.3
Truncatedd
ART, no depressive symptoms 34 2,517 1.36 1 0.78
ART, depressive symptoms 80 1,877 4.27 3.32 1.99, 5.54
No ART, no depressive symptoms 33 1,348 2.47 2.25 1.14, 4.43
No ART, depressive symptoms 80 1,129 7.06 6.64 3.69, 11.9
Weightede
ART, no depressive symptoms 49 2,813 1.73 1 0.92
ART, depressive symptoms 86 2,037 4.21 3.23 1.61, 6.47
No ART, no depressive symptoms 32 1,366 2.36 1.94 0.91, 4.15
No ART, depressive symptoms 87 1,133 7.64 6.58 3.28, 13.2
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard
ratio; IR, incidence rate.
a Incidence rate per 100 women-years.
b P value for the term for interaction between the 2 joint exposures, ART initiation and depressive symptoms.
c Weighted models adjusted for age at enrollment, race, CD4 cell count, log10 HIV RNA, baseline CD4 cell count,
and baseline log10 HIV RNA. Weights for depressive symptoms also adjusted for depressive symptoms at the previ-
ous visit.
d Weights truncated at 0.1 and 10.
e Weighted models further adjusted for substance abuse.
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Collaboration (40). Although we cannot preclude the possibil-
ity of interaction between these 2 exposures, the protective
effect of ART was similar to prior estimates when examined
jointly with depressive symptoms. The effect of depressive
symptoms on mortality is less clearly demonstrated in the lit-
erature. Results prior to the advent of modern combination
ART indicated no effect of depressive symptoms on mortality
(21); yet more recent studies have shown a harmful effect
(14–20). Our results similarly indicate a harmful effect of
depressive symptoms on mortality.
The risk of major depression in HIV-infected women is
much higher than in HIV-infected men and is associated with
disease progression (6, 20). Depression is associated with
impaired immunity among HIV-infected women (6, 20, 41,
42). Depression reduces natural killer cell activity and increases
CD8 T-lymphocyte activity and viral load, which is one possi-
ble mechanism through which depression may increase mor-
tality (6, 20, 41, 42).
A causal interpretation of our results requires the assump-
tions of treatment-variation irrelevance (essentially consis-
tency), no interference, conditional exchangeability, positivity,
and correct model specification. Treatment-variation irrele-
vance is the assumption that the means through which a treat-
ment or exposure is delivered is irrelevant to the potential
outcome (37). More informally, treatment-variation irrelevance
requires that there is either a single version of treatment, or that
the multiple versions are exchangeable. Many versions of
ART existed throughout the study period; our assumption of
treatment-variation irrelevance is strong but a necessary sim-
plifying assumption given the size of our cohort and number
of regimens. Additionally, the dichotomization of depressive
symptoms may be a violation of treatment-variation irrele-
vance, but it is the typical interpretation of the CES-D in the
existing literature and is necessary for stable estimates in
these data. The assumption of no interference between sub-
jects requires that an individual’s outcome is independent of
the treatment received by other individuals, which seems a
reasonable assumption in this cohort (38). Conditional
exchangeability occurs when potential outcomes are indepen-
dent of the treatment received given measured confounders
(36, 39). This is often informally stated as “no unmeasured
confounding and no informative censoring.” As with most
M
or
ta
lit
y 
In
ci
de
nc
e,
 %
 
0
10
20
30
40
50
60
Time Since ART Initiation, years
0 1 2 3 87654
Figure 3. Joint effects of antiretroviral therapy (ART) initiation and depressive symptoms on cumulative mortality in the Women’s Interagency
HIV Study, United States, 1998–2011. Women with depressive symptoms who had not initiated ART are represented by the solid black line,
women with depressive symptoms who had initiated ART by the solid gray line; women without depressive symptoms who had not initiated ART
by the dashed black line, and women without depressive symptoms who had initiated ART by the dashed gray line. Weighted models adjusted for
age at enrollment, race, CD4 cell count, log10 HIV RNA, baseline CD4 cell count, and baseline log10 HIV RNA. Weights for depressive symptoms
also adjusted for depressive symptoms at the previous visit.
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observational studies, unmeasured confounding is a possible
source of bias in our study. Positivity requires that for all com-
binations of confounders, there is a nonzero probability of
receiving the treatments (36). If treatment is not possible for a
particular confounding level, then the positivity assumption is
violated. Given our relatively limited adjustment set and well-
behaved weights, we consider any violations of the positivity
assumption to be minor. Our weights also provide some sup-
port for the assumption of correct model specification.
Some aspects of the study design may limit our inferences.
Of note, the sample size of the study was relatively small, as
indicated bymodest precision of our estimates.We considered
the restriction of our study sample to women without preva-
lent ART use to be important in preventing prevalent-user bias
(30), but this restriction did limit the sample and resulting pre-
cision. Our assumption that ART use was constant after ART
initiation is optimistic. Although women are counseled on the
importance of adherence to therapy, interruptions of therapy
occur and may be the result of depressive symptoms (42).
However, we interrogated this assumption with a sensitivity
analysis where we allowed ART use to vary over time. We
also used a measurement for depression (depressive symp-
toms) that is based upon a dichotomization of a continuous,
imperfect assessment. The CES-D, used to measure depres-
sive symptoms, may be limited as a mortality predictor in a
population experiencing high morbidity due to overlap with
somatic symptoms such as poor appetite and fatigue. Finally,
as with all models, misspecification is a concern. While our
relatively well-behaved weights provide circumstantial evi-
dence against model misspecification, the potential for bias
due to model misspecification remains.
Our study addressed the joint effects of ART initiation and
depressive symptoms in a population of HIV-infected women.
We highlight the need for continued attention by HIV provi-
ders to the mental health, including specific conditions such
as depression, of their patients. We report a strong protective
effect of ART initiation on mortality in HIV-infected women
and a harmful effect of depressive symptoms on mortality.
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